The promise of atypical antipsychotics
- 1 October 2004
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 116 (4) , 49-63
- https://doi.org/10.3810/pgm.2004.10.1601
Abstract
Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics. In this article, the authors discuss the advantages and side effects of these agents and present a guide to help physicians choose the optimal drug in the most favorable formulation for each patient.Keywords
This publication has 21 references indexed in Scilit:
- Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of SchizophreniaA Randomized Controlled TrialJAMA, 2003
- A Meta-analysis of the Efficacy of Second-Generation AntipsychoticsArchives of General Psychiatry, 2003
- Clozapine Treatment for Suicidality in SchizophreniaInternational Suicide Prevention Trial (InterSePT)Archives of General Psychiatry, 2003
- Managing Treatment-Resistant Schizophrenia: Evidence from Randomized Clinical TrialsJournal of Psychiatric Practice, 2002
- Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Atypical antipsychotics: revolutionary or incremental advance?Expert Review of Neurotherapeutics, 2002
- Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With SchizophreniaPsychiatric Services, 2001
- Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ, 2000
- New antipsychotic medicationsPostgraduate Medicine, 1997